News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
372,019 Results
Type
Article (24978)
Company Profile (325)
Press Release (346716)
Multimedia
Podcasts (58)
Webinars (7)
Section
Business (104173)
Career Advice (900)
Deals (17586)
Drug Delivery (46)
Drug Development (67883)
Employer Resources (77)
FDA (9069)
Job Trends (7895)
News (195550)
Policy (16094)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioMidwest Digital (5)
2024 Bio NC Digital (8)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (8)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (1565)
Accelerated approval (5)
Adcomms (24)
Allergies (69)
Alliances (28574)
ALS (72)
Alzheimer's disease (1025)
Antibody-drug conjugate (ADC) (127)
Approvals (9070)
Artificial intelligence (165)
Autoimmune disease (24)
Automation (8)
Bankruptcy (157)
Best Places to Work (6904)
BIOSECURE Act (6)
Biosimilars (65)
Biotechnology (270)
Bladder cancer (62)
Brain cancer (28)
Breast cancer (247)
Cancer (2032)
Cardiovascular disease (140)
Career advice (742)
Career pathing (11)
CAR-T (143)
Cell therapy (380)
Cervical cancer (17)
Clinical research (55237)
Collaboration (653)
Compensation (339)
Complete response letters (18)
COVID-19 (2070)
CRISPR (41)
C-suite (181)
Cystic fibrosis (85)
Data (1818)
Decentralized trials (1)
Denatured (11)
Depression (35)
Diabetes (178)
Diagnostics (2955)
Digital health (7)
Diversity (3)
Diversity, equity & inclusion (18)
Drug discovery (99)
Drug pricing (40)
Drug shortages (6)
Duchenne muscular dystrophy (91)
Earnings (39682)
Editorial (26)
Employer branding (8)
Employer resources (70)
Events (64239)
Executive appointments (499)
FDA (9925)
Featured Employer (35)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (566)
Gene editing (99)
Generative AI (17)
Gene therapy (264)
GLP-1 (513)
Government (2249)
Grass and pollen (3)
Guidances (31)
Healthcare (10093)
Huntington's disease (22)
IgA nephropathy (26)
Immunology and inflammation (121)
Indications (25)
Infectious disease (2194)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (37)
Intellectual property (76)
Interviews (171)
IPO (9280)
IRA (20)
Job creations (1387)
Job search strategy (637)
Kidney cancer (10)
Labor market (14)
Layoffs (314)
Leadership (12)
Legal (2270)
Liver cancer (63)
Lung cancer (301)
Lymphoma (127)
Machine learning (3)
Management (30)
Manufacturing (165)
MASH (55)
Medical device (3973)
Medtech (3974)
Mergers & acquisitions (8688)
Metabolic disorders (483)
Multiple sclerosis (67)
NASH (14)
Neurodegenerative disease (79)
Neuropsychiatric disorders (26)
Neuroscience (1465)
NextGen: Class of 2025 (2954)
Non-profit (1683)
Northern California (2004)
Now hiring (24)
Obesity (243)
Opinion (158)
Ovarian cancer (74)
Pain (50)
Pancreatic cancer (73)
Parkinson's disease (130)
Partnered (9)
Patents (154)
Patient recruitment (82)
Peanut (45)
People (31926)
Pharmaceutical (55)
Pharmacy benefit managers (6)
Phase I (18245)
Phase II (24734)
Phase III (17736)
Pipeline (946)
Policy (69)
Postmarket research (1593)
Preclinical (7381)
Press Release (42)
Prostate cancer (97)
Psychedelics (35)
Radiopharmaceuticals (250)
Rare diseases (336)
Real estate (2158)
Recruiting (30)
Regulatory (13058)
Reports (20)
Research institute (1674)
Resumes & cover letters (147)
Rett syndrome (4)
RNA editing (4)
RSV (45)
Schizophrenia (62)
Series A (106)
Series B (63)
Service/supplier (2)
Sickle cell disease (47)
Southern California (1679)
Special edition (12)
Spinal muscular atrophy (123)
Sponsored (18)
Startups (2299)
State (1)
Stomach cancer (14)
Supply chain (32)
Tariffs (9)
The Weekly (46)
United States (15898)
Vaccines (615)
Venture capitalists (32)
Weight loss (140)
Women's health (17)
Worklife (7)
Date
Last 7 days (332)
Last 30 days (1637)
Last 365 days (24590)
2025 (6936)
2024 (25970)
2023 (28810)
2022 (34818)
2021 (36552)
2020 (32001)
2019 (23487)
2018 (17356)
2017 (19288)
2016 (17567)
2015 (20650)
2014 (15111)
2013 (11171)
2012 (11513)
2011 (11392)
2010 (10707)
Location
Africa (353)
Alabama (43)
Alaska (3)
Arizona (80)
Arkansas (6)
Asia (23499)
Australia (4211)
California (4461)
Canada (1296)
China (402)
Colorado (181)
Connecticut (186)
Delaware (122)
Europe (52902)
Florida (600)
Georgia (139)
Idaho (23)
Illinois (299)
India (13)
Indiana (175)
Iowa (3)
Japan (118)
Kansas (66)
Kentucky (14)
Louisiana (3)
Maine (48)
Maryland (586)
Massachusetts (3522)
Michigan (83)
Minnesota (180)
Mississippi (1)
Missouri (33)
Montana (17)
Nebraska (6)
Nevada (30)
New Hampshire (23)
New Jersey (1263)
New Mexico (14)
New York (1285)
North Carolina (643)
North Dakota (4)
Northern California (2004)
Ohio (132)
Oklahoma (9)
Oregon (24)
Pennsylvania (822)
Puerto Rico (5)
Rhode Island (17)
South America (454)
South Carolina (6)
Southern California (1679)
Tennessee (36)
Texas (596)
Utah (75)
Virginia (101)
Washington D.C. (35)
Washington State (402)
Wisconsin (38)
372,019 Results for "immune onc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche
February 27, 2025
·
6 min read
Biotech Bay
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced the company will present Phase 1b interim data for IO-202 in patients with chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association (EHA) Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
May 14, 2024
·
5 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
June 14, 2024
·
6 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced a Phase 1b/2 clinical trial collaboration with Roche to evaluate Immune-Onc’s IO-108, a first-in-class antibody targeting LILRB2 (also known as ILT4), in combination with Roche’s atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
February 20, 2024
·
6 min read
Press Releases
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting
December 9, 2024
·
7 min read
Press Releases
Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel Disease at ECCO 2025
February 21, 2025
·
4 min read
Press Releases
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 11, 2025
·
14 min read
Startups
GSK-backed Ouro Launches With $120M to ‘Reset’ the Immune System
Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated diseases.
January 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for Inflammatory Bowel Disease
February 17, 2025
·
2 min read
1 of 37,202
Next
